Published in
Rockefeller University Press, Journal of Experimental Medicine, 9(217), 2020
DOI: 10.1084/jem.20201342
Links
Tools
Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
Journal article published in 2020 by
Lars M. Koenig 
,
Daniel F. R. Boehmer ,
Philipp Metzger,
Max Schnurr ,
Stefan Endres ,
Simon Rothenfusser
,
Daniel F. R. Boehmer ,
Philipp Metzger,
Max Schnurr ,
Stefan Endres ,
Simon Rothenfusser
This paper is made freely available by the publisher.
Full text: Download
Postprint:
archiving forbidden
Data provided by 
Abstract
An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.